SMHGF (SMHGF PINK) stock market data APIs
$0.6959
0(0%)
as of July 18, 2025
Try our APIs with
free plan!
SMHGF Financial Data Overview
Price chart is built with
Anychart
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN simnotrelvir tablets and ritonavir tablets. The company also offers promotional services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients and its property management business. The company was founded in 1995 and is headquartered in Nanjing, China.
Prev. Close
0.6959
Open
0.6959
High
0.6959
Low
0.6959
52 wk Range
0.6699-0.7585
Market Cap
1 771 M
P/E Ratio
17.305
Shares Outstanding
2 475 M
Revenue
6 635 M
Dividends (Yield)
0.2311
Beta
0.567
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SMHGF data using free add-ons & libraries
Get SMHGF Fundamental Data
SMHGF Fundamental data includes:
- Net Revenue: 6 635 M
- EBITDA: 1 356 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SMHGF News
New
Revealing Undervalued Asian Stocks Including Simcere Pharmaceutical Group And Two Others
As global markets navigate a period of mixed economic signals and geopolitical tensions, Asian stocks present intriguing opportunities for investors seeking value. In this environment, identifying und...
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment ...
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
NextCure NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights Phase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is ...
How to Hold Onto Your Paychecks in This IPO Frenzy
(Bloomberg Opinion) -- Now that we’re all stuck at home, speculating on new initial public offerings has become a thrilling pastime. But as Hong Kong experiences its best IPO market in a decade, a w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
